References: |
US Biological application references: 1. Escobar, A. et al., (2005) Clin Exp Immunol. 142:555-568. 2. LOpez, M.N. et al., (2007) Investigative Ophthalmology and Visual Science 48:1219-1227. 1. Optimisation of the CT h4S bioassay for detection of human interleukin-4 secreted by mononuclear cells stimulated by phytohaemaglutinin or by human leukocyte antigen mismatched mixed lymphocyte culture. Petersen SL, Russell CA, Vindelov LL, Immunol Lett 2002 Oct 21;84(1):29-39
2. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. Whitehead RP, Lew D, Weiss GR, Crawford ED, J Immunother 2002 Jul-Aug;25(4):352-8
3. Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR. Ekerfelt C, Ernerudh J. J Immunol Methods 2002 Feb 1;260(1-2):55-67
4. Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter. Casolaro V, Keane-Myers AM, Steindler C, Ono SJ, J Biol Chem 2000 Nov 24;275(47):36605-11
5. A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer. Davis ID, Maher DW, Green MD, Boyd AW, Growth Factors 2000;17(4):287-300
6. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Okada H, Attanucci J, Pollack IF, Cancer Gene Ther 2000 Mar;7(3):486-94 |